Ratan Tata invests in Generic Aadhaar to bring affordable medicine to help more and more poor.

Arjun Deshpande, who is the founder of the Generic Aadhar and he is a kid of 17 years and India’s Youngest Entrepreneur. It supplies quality generic drugs from reputed manufacturers at up to 80 per cent lower price than market.

On May 8, 2020, Ratan Tata, a great businessman and since his retirement, he has invested hundreds of crore rupees in the start-ups and he has invested an undisclosed amount in a Generic Aadhaar founded by a 17 years old kid, Arjun Deshpande.

This boy, a alumni of DAV Public School, Thana and his aimed to bring affordable price of medicine to the poor and this aim became his path to start his journey from 0.

Ratan Tata, he has invested in dozen of start-ups since he retired in December 2012 and Ola, Paytm, Snapdeal, CureFit, etc. these are the some example in which he invested.

Arjun Deshpande, a young and talented boy, who came with their innovative and supportive idea and converted it and made his aim. He chooses his own path to help the poorer. So, he founded Generic Aadhaar, which is a source  of generic drugs, buy directly from manufacturers and sells it to the retailers, this direct process eliminate approx. 16-20 per cent wholesaler margins.

Arjun Deshpande whose annual revenue as start-up Rs. 6 crore and the next three years, he is looking for a revenue of Rs. 150-200 crore and he has recently 55 person as a employees and it includes pharmacists, IT engineers and marketing professionals.

Arjun Deshpande, founder and Chief Executive of Generic Aadhaar, said “Our business model gives us an edge over others as we aim to bring affordable healthcare to millions. Our missin is to provide senior citizens and pensioner the care they deserve by delivering in expensive medicine.

Generic Aadhaar will provide all their support to the unorganized sector by different ways like bringing right technology, IT infrastructure, etc and currently they are supplying drugs for diabetes and hypertension, but soon they will supply the cancer drugs in a lower price than markets.